Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study

Background: Although effective, current chimeric antigen receptor T-cell (CAR-T) production methods-centralized, manual, and complex-are cost-intensive, time-consuming, and prone to variability. AIDPATH (AI-Powered Decentralized Production for Advanced Therapies in the Hospital) proposes a decentralized, automated alternative that integrates patient-specific data; optimizes resource use; and potentially improves cell viability, manufacturing efficiency, and patient outcomes. Objective: The aim of this study was…

By the Truvace deskOctober 14, 20262 min read1 sourcePeer-reviewedTRV-2026-1372· cite & verify

In brief

Researchers ran an early health technology assessment of AIDPATH, a decentralized, automated, AI-supported way of making CAR-T cell therapy inside hospitals. They compared it with the commercial product cilta-cel and with standard of care in patients with triple-class refractory multiple myeloma, using a 40-year horizon and the perspective of German hospitals.

The result matters because CAR-T therapy is effective but costly and complex to produce, so a cheaper in-hospital route could inform reimbursement discussions. The conclusion rests on a model that used estimated rather than observed parameters for AIDPATH, which is still in development, so the favorable result is a projection and not a demonstrated outcome.

Main points

The study used a partitioned survival model with three states: progression-free disease, progressed disease, and death.
Cilta-cel inputs came from clinical trial data, standard of care inputs from real-world data, and AIDPATH inputs from estimates.
Most CAR-T costs were driven by acquisition and adverse events.
Results were most sensitive to discount rates and progression-free survival assumptions.
Scenarios with fewer adverse events and shorter vein-to-vein times further supported AIDPATH's cost-effectiveness.

The gain

In a partitioned survival model, the AI-supported AIDPATH platform came out dominant over both cilta-cel and standard of care for triple-class refractory multiple myeloma from the German hospital perspective.

The rundown

The background describes current CAR-T production as centralized, manual, and complex, making it cost-intensive, slow, and prone to variability. AIDPATH proposes a decentralized, automated alternative that integrates patient-specific data and optimizes resource use.

The primary outcome was the incremental cost-effectiveness ratio, with sensitivity and scenario analyses as secondary outcomes. The model found AIDPATH dominant against both comparators. Sensitivity analyses identified discount rates and progression-free survival assumptions as the biggest influences.

The authors describe this as the first study to assess the cost-effectiveness of an AI-supported CAR-T product in Germany from the hospital perspective. They call AIDPATH a promising option for future implementation and say further data are needed.